• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit/AskCarlat AI
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » General Psychiatry » OxMIS: A Free Online Suicide Assessment Tool
Research Update

OxMIS: A Free Online Suicide Assessment Tool

October 1, 2026
Kamron Fariba, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Kamron Fariba, MD. Dr. Fariba has no financial relationships with companies related to this material.

PDF


Getting your Trinity Audio player ready...

REVIEW OF: Torino G et al, J Affect Disord 2025;381:321–328
STUDY TYPE: Meta-analysis

The Oxford Mental Illness and Suicide tool (OxMIS; https://oxrisk.com/oxmis) is a free and validated online calculator of suicide risk in patients with bipolar or schizophrenia spectrum disorders. Users input 17 clinical and social variables for a patient and receive an estimate of that patient’s risk of attempting suicide within the next 12 months. This study assessed the evidence for OxMIS.

From the two studies they included, researchers calculated a pooled odds ratio of 3.42 (95% CI: 3.09–3.77) for OxMIS, indicating that patients categorized as high risk were over 3 times more likely to die by suicide than their low-risk counterparts. Sensitivity and specificity in the studies were around 55% and 70%, respectively, meaning the tool is better at ruling out risk than ruling it in. The authors noted, “Half of the clinicians rated the OxMIS as providing an accurate representation of suicide risk, with a moderate correlation between the OxMIS and their clinical judgment of risk (r s (58) = 0.51, p < 0.001).” They reported that OxMIS was feasible to implement in routine clinical workflow.

CARLAT TAKE
This meta-analysis incorporated limited evidence and offers lukewarm support for OxMIS. For patients with bipolar disorder or schizophrenia spectrum disorders, OxMIS is more helpful for determining who is not at elevated suicide risk—but when it does determine a patient is high risk, that deserves consideration. It’s a free online tool with evidence to support it; so, should we add it to our armamentarium? For now, consider it a research-supported supplement for good clinical judgment and not a replacement for your own risk assessment.

General Psychiatry
KEYWORDS bipolar disorder OxMIS risk calculator schizophrenia spectrum disorders suicide risk assessment
    Kamron Fariba, MD

    LAIs for Bipolar Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: October 1, 2026
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Ketamine, TCPR, October 2026
    Top 10 Prescribing Tips for Working with Teens and Kids
    An Update on Ketamine
    Bupropion for Anxious Depression: Not as Activating as You Think
    Clozapine Shows Best Persistence in Real-World Oral Antipsychotic Use
    OxMIS: A Free Online Suicide Assessment Tool
    CME Post-Test, Ketamine, TCPR, 2026
    DOWNLOAD NOW
    Featured Book
    • MFB8e_SpiralCover.png

      Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

      Updated 2026 prescriber's guide.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2850155913.jpg
      General Psychiatry

      ADHD Undone: The Corporate Practice of Medicine

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.